Attached files

file filename
8-K - 8-K - MAGELLAN HEALTH INCa13-6184_18k.htm

Exhibit 99.1

 

GRAPHIC

NEWS RELEASE

 

Media Contact: David Carter, dwcarter@magellanhealth.com, (860) 507-1909

Investor Contact: Renie Shapiro, rshapiro@magellanhealth.com, (877) 645-6464

 

 

MAGELLAN HEALTH SERVICES REPORTS

FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS

 

AVON, Conn. — February 28, 2013 — Magellan Health Services Inc. (NASDAQ: MGLN) today reported financial results for the fourth quarter and full year 2012, as summarized below. For the year ended December 31, 2012, the company reported net revenue of $3,207.4 million, segment profit of $267.4 million, and net income of $151.0 million or $5.42 per diluted common share.  Segment profit represents income from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes.

 

Financial Results

 

 

 

Three Months Ended December 31

 

Year Ended December 31

 

(Millions, except per share results)

 

2012

 

2011

 

Increase/
(Decrease)

 

2012

 

2011

 

Increase/
(Decrease)

 

Revenue

 

$

830.3

 

$

721.5

 

15.1

%

$

3,207.4

 

$

2,799.4

 

14.6

%

Segment Profit

 

77.7

 

63.2

 

22.9

%

267.4

 

270.4

 

(1.1

)%

Net Income

 

37.0

 

29.7

 

24.6

%

151.0

 

129.6

 

16.5

%

Earnings per Share

 

1.32

 

1.05

 

25.7

%

5.42

 

4.17

 

30.0

%

 

As of December 31, 2012, the company had unrestricted cash and investments of $302.3 million.

 

“Magellan had a strong fourth quarter, and completed a successful 2012,” said Barry M. Smith, chief executive officer.  “Each of our business units contributed to our success with significant accomplishments including solid financial results, product innovation, and new business sales.

 

“This is an exciting time as we enter a new phase of growth.  The next twenty-four to thirty-six months will be especially dynamic, as the industry consolidates and the Affordable Care Act is implemented with Medicaid expansion and the creation of state, federal and commercial exchanges.  As a result of these changes, we foresee market disruption for the traditional players, allowing for significant growth opportunities for innovative, agile companies such as Magellan.

 

“During 2013, we will continue investing to expand our presence in the Pharmacy marketplace as well as in Medicaid.  In Pharmacy, customers face a fragmented and inefficient system which compromises quality care and increases costs.  Our vision is to create an entirely new approach, so that we can lower the total drug spend while improving the health of the patients we serve. We offer a suite of clinical and cost management solutions that integrate our specialty, medical pharmacy, and PBM capabilities. Our solutions offer customers a comprehensive approach to managing the quality and cost of pharmaceutical care, for any drug, at any provider site of service, under any benefit.

 

“We are also gaining traction on our Medicaid initiatives where we have created new models of care for special populations that integrate the pharmaceutical, physical and behavioral health management of individuals with

 

Magellan Health Services—55 Nod Road, Avon CT 06001—www.MagellanHealth.com

 



 

Serious Mental Illness as well as those dually eligible for Medicaid and Medicare.  Whether through our traditional businesses or through innovating and implementing new strategies for growth, Magellan is well positioned to shape the future of health care.”

 

Outlook

 

“We completed a strong 2012, exceeding our segment profit guidance for the year,” said Jonathan N. Rubin, chief financial officer.  “We posted high quality results, reflecting key new business implementations, improved cost of care management, and a lower administrative expense ratio.  We achieved these results, while making significant investments in our Medicaid and Pharmacy strategies. Combined with our financial strength, this positions us well for 2013 and beyond.

 

“We are reaffirming our guidance for 2013, which calls for net revenue in the range of $3.56 billion to $3.74 billion, and net income in the range of $91 million to $109 million. Additionally, we expect segment profit for 2013 to be in the range of $250 million to $270 million.  Based upon the impact of share repurchase activity through February 22, 2013, but not considering any potential future share repurchases, we are adjusting our diluted weighted average shares outstanding for the year to 27.8 million, resulting in an EPS range of $3.27 to $3.92.”

 

Earnings Results Conference Call

 

Management will host a conference call at 10:00 a.m. Eastern Time on Thursday, February 28, 2013.  To participate in the conference call, interested parties should call 1-888-566-8408 and reference the pass code Fourth Quarter Earnings Call 2012 approximately 15 minutes before the start of the call.  The conference call will also be available via a live Webcast at Magellan’s investor relations page at www.MagellanHealth.com.

 

About Magellan Health Services
Headquartered in Avon, Conn., Magellan Health Services Inc. is a leading specialty health care management organization with expertise in managing behavioral health, radiology and specialty pharmaceuticals, as well as public sector pharmacy benefits programs. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve.  As of December 31, 2012, Magellan’s customers include health plans, employers and government agencies, serving approximately 33.8 million members in our behavioral health business, 17.2 million members in our radiology benefits management segment, and 8 million members in our medical pharmacy management product.  In addition, the specialty pharmaceutical segment served 41 health plans and employers, and several pharmaceutical manufacturers and state Medicaid programs.  The company’s Medicaid Administration segment served 24 states and the District of Columbia.  For more information, visit www.MagellanHealth.com.

 

Cautionary Statement

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties.  All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2013 revenue, net income, segment profit, earnings per share, strategy and growth. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s

 

2



 

customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission on February 28, 2012, the company’s subsequent Quarterly Reports on Form 10-Q filed during 2012 and the company’s Annual Report on Form 10-K for the year ended December 31, 2012, expected to be filed with the Securities and Exchange Commission and posted on the company’s website later today.  Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure.  Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

 

Media Contact

David W. Carter

860-507-1909

DWCarter@MagellanHealth.com

 

Investor Contact

Renie Shapiro

877-645-6464

RShapiro@MagellanHealth.com

 

# # #

 

3



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share amounts)

 

 

 

Three Months Ended December 31,

 

Year Ended December 31,

 

 

 

2011

 

2012 (1)

 

2011

 

2012 (1)

 

 

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue:

 

 

 

 

 

 

 

 

 

Managed care and other

 

$

652,804

 

$

742,950

 

$

2,551,991

 

$

2,857,099

 

Dispensing

 

68,660

 

87,324

 

247,409

 

350,298

 

Total net revenue

 

721,464

 

830,274

 

2,799,400

 

3,207,397

 

 

 

 

 

 

 

 

 

 

 

Cost and expenses:

 

 

 

 

 

 

 

 

 

Cost of care

 

461,527

 

528,529

 

1,784,724

 

2,071,890

 

Cost of goods sold

 

64,479

 

82,859

 

232,038

 

328,414

 

Direct service costs and other operating expenses (2) 

 

136,250

 

145,016

 

529,634

 

557,512

 

Depreciation and amortization

 

15,335

 

15,316

 

58,623

 

60,488

 

Interest expense

 

1,080

 

534

 

2,502

 

2,247

 

Interest income

 

(516

)

(400

)

(2,781

)

(2,019

)

Total costs and expenses

 

678,155

 

771,854

 

2,604,740

 

3,018,532

 

Income before income taxes

 

43,309

 

58,420

 

194,660

 

188,865

 

Provision for income taxes

 

13,570

 

21,418

 

65,037

 

37,838

 

Net income

 

29,739

 

37,002

 

129,623

 

151,027

 

Other comprehensive income (loss) (3) 

 

143

 

(93

)

(159

)

115

 

Comprehensive income

 

$

29,882

 

$

36,909

 

$

129,464

 

$

151,142

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding — basic

 

27,724

 

27,505

 

30,478

 

27,386

 

Weighted average number of common shares outstanding — diluted

 

28,300

 

28,020

 

31,058

 

27,882

 

 

 

 

 

 

 

 

 

 

 

Net income per common share — basic

 

$

1.07

 

$

1.35

 

$

4.25

 

$

5.51

 

Net income per common share — diluted

 

$

1.05

 

$

1.32

 

$

4.17

 

$

5.42

 

 


(1)         For a more detailed discussion of Magellan’s results for the period ended December 31, 2012, refer to the Company’s Annual Report on Form 10-K, which will be filed with the SEC on Thursday, February 28, 2013, and the live broadcast or taped replay of the Company’s earnings conference call on Thursday, February 28, 2013, which will be available at www.MagellanHealth.com.

 

(2)         Includes stock compensation expense of $4,010 and $3,848 for the three months ended December 31, 2011 and 2012, respectively, and $17,418 and $17,783 for the years ended December 31, 2011 and 2012, respectively.

 

(3)         Net of income tax provision (benefit) of $87 and $(61) for the three months ended December 31, 2011 and 2012, respectively, and and $(102) and $73 for the years ended December 31, 2011 and 2012, respectively.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2011

 

2012 (1)

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

129,623

 

$

151,027

 

 

 

 

 

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

58,623

 

60,488

 

Non-cash interest expense

 

1,033

 

728

 

Non-cash stock compensation expense

 

17,418

 

17,783

 

Non-cash income tax expense

 

8,285

 

17,306

 

Non-cash amortization on investments

 

12,309

 

7,193

 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

 

 

 

 

 

Restricted cash (2) 

 

(69,060

)

(40,760

)

Accounts receivable, net

 

(15,609

)

(16,411

)

Pharmaceutical inventory

 

(11,657

)

(6,160

)

Other assets

 

3,804

 

414

 

Accounts payable and accrued liabilities

 

(7,251

)

(8,321

)

Medical claims payable and other medical liabilities

 

(7,905

)

31,292

 

Tax contingencies

 

(9,453

)

(35,376

)

Other

 

1,843

 

2,090

 

Net cash provided by operating activities

 

112,003

 

181,293

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Capital expenditures

 

(54,394

)

(69,549

)

Acquisitions and investments in businesses, net of cash acquired

 

(376

)

 

Purchase of investments

 

(259,552

)

(321,541

)

Maturity of investments

 

330,583

 

281,748

 

Investment in equity method joint ventures

 

 

(1,225

)

Net cash provided by (used in) investing activities

 

16,261

 

(110,567

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments on long-term debt and capital lease obligations

 

(559

)

 

Payments to acquire treasury stock

 

(407,645

)

(21,868

)

Proceeds from issuance of equity

 

20,000

 

 

Proceeds from exercise of stock options and warrants

 

41,796

 

20,486

 

Tax benefit from exercise of stock options and vesting of stock awards

 

2,038

 

990

 

Other

 

(1,211

)

(732

)

Net cash used in financing activities

 

(345,581

)

(1,124

)

 

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

 

(217,317

)

69,602

 

Cash and cash equivalents at beginning of period

 

337,179

 

119,862

 

Cash and cash equivalents at end of period

 

$

119,862

 

$

189,464

 

 


(1)         The Company’s Annual Report on Form 10-K for the year ended December 31, 2012 will be filed with the SEC on Thursday, February 28, 2013.

 

(2)         Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change.  During the years ended December 31, 2011 and 2012, restricted investments of $62,298 and $16,660, respectively, were shifted to restricted cash that resulted in an operating cash flow use.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT

(In thousands)

 

 

 

Three Months Ended December 31,

 

Years Ended December 31,

 

 

 

2011

 

2012 (1)

 

2011

 

2012 (1)

 

 

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Managed care and other revenue

 

 

 

 

 

 

 

 

 

- Commercial

 

$

136,694

 

$

193,048

 

$

561,780

 

$

728,512

 

- Public Sector

 

384,755

 

414,586

 

1,459,659

 

1,620,875

 

- Radiology Benefits Management

 

85,856

 

95,324

 

344,335

 

349,133

 

- Specialty Pharmaceutical Management

 

13,895

 

14,475

 

48,534

 

55,178

 

- Medicaid Administration (2) 

 

52,831

 

41,348

 

220,453

 

172,491

 

- Elimination (2) 

 

(21,227

)

(15,831

)

(82,770

)

(69,090

)

Total managed care and other revenue

 

652,804

 

742,950

 

2,551,991

 

2,857,099

 

 

 

 

 

 

 

 

 

 

 

Dispensing revenue - Specialty Pharmaceutical Management

 

68,660

 

87,324

 

247,409

 

350,298

 

 

 

 

 

 

 

 

 

 

 

Cost of care

 

 

 

 

 

 

 

 

 

- Commercial

 

78,240

 

113,526

 

314,178

 

437,518

 

- Public Sector (2) 

 

337,870

 

354,936

 

1,271,532

 

1,413,320

 

- Radiology Benefits Management

 

47,509

 

62,019

 

205,240

 

228,383

 

- Medicaid Administration

 

19,135

 

13,879

 

76,544

 

61,759

 

- Elimination (2) 

 

(21,227

)

(15,831

)

(82,770

)

(69,090

)

Total cost of care

 

461,527

 

528,529

 

1,784,724

 

2,071,890

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold - Specialty Pharmaceutical Management

 

64,479

 

82,859

 

232,038

 

328,414

 

 

 

 

 

 

 

 

 

 

 

Direct service costs and other operating expenses

 

 

 

 

 

 

 

 

 

- Commercial

 

39,258

 

44,210

 

152,760

 

172,035

 

- Public Sector

 

17,024

 

22,279

 

67,227

 

89,129

 

- Radiology Benefits Management

 

14,401

 

14,305

 

61,681

 

55,418

 

- Specialty Pharmaceutical Management

 

5,686

 

6,965

 

24,344

 

26,709

 

- Medicaid Administration

 

25,198

 

21,096

 

103,254

 

84,884

 

- Corporate

 

34,683

 

36,161

 

120,368

 

129,337

 

Total direct service costs and other operating expenses

 

136,250

 

145,016

 

529,634

 

557,512

 

 

 

 

 

 

 

 

 

 

 

Stock compensation expense (3)

 

 

 

 

 

 

 

 

 

- Commercial

 

(162

)

298

 

(839

)

(532

)

- Public Sector

 

(218

)

(276

)

(872

)

(1,111

)

- Radiology Benefits Management

 

(325

)

(388

)

(1,563

)

(1,567

)

- Specialty Pharmaceutical Management

 

(54

)

(227

)

(693

)

(672

)

- Medicaid Administration

 

(24

)

(76

)

(124

)

(335

)

- Corporate

 

(3,227

)

(3,179

)

(13,327

)

(13,566

)

Total stock compensation expense

 

(4,010

)

(3,848

)

(17,418

)

(17,783

)

 

 

 

 

 

 

 

 

 

 

Segment profit (loss)

 

 

 

 

 

 

 

 

 

- Commercial

 

19,358

 

35,014

 

95,681

 

119,491

 

- Public Sector

 

30,079

 

37,647

 

121,772

 

119,537

 

- Radiology Benefits Management

 

24,271

 

19,388

 

78,977

 

66,899

 

- Specialty Pharmaceutical Management

 

12,444

 

12,202

 

40,254

 

51,025

 

- Medicaid Administration

 

8,522

 

6,449

 

40,779

 

26,183

 

- Corporate and Elimination

 

(31,456

)

(32,982

)

(107,041

)

(115,771

)

Total segment profit

 

$

63,218

 

$

77,718

 

$

270,422

 

$

267,364

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of segment profit to income before income taxes:

 

 

 

 

 

 

 

 

 

Segment profit

 

$

63,218

 

$

77,718

 

$

270,422

 

$

267,364

 

Stock compensation expense

 

(4,010

)

(3,848

)

(17,418

)

(17,783

)

Depreciation and amortization

 

(15,335

)

(15,316

)

(58,623

)

(60,488

)

Interest expense

 

(1,080

)

(534

)

(2,502

)

(2,247

)

Interest income

 

516

 

400

 

2,781

 

2,019

 

Income before income taxes

 

$

43,309

 

$

58,420

 

$

194,660

 

$

188,865

 

 


(1)         The Company’s Annual Report on Form 10-K for the year ended December 31, 2012 will be filed with the SEC on Thursday, February 28, 2013.

 

(2)         Public Sector has subcontracted with Medicaid Administration to provide pharmacy benefits management services on a limited risk basis for one of Public Sector’s customers.  As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3)         Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.